Traitement en cours

Veuillez attendre...

PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le dimanche 05.04.2020 à 10:00 AM CEST
Paramétrages

Paramétrages

1. WO2005003372 - GENE MYLK UTILISE EN TANT QUE MODIFICATEUR DE LA MORPHOGENESE RAMIFIEE ET PROCEDES D'UTILISATION CORRESPONDANT

Numéro de publication WO/2005/003372
Date de publication 13.01.2005
N° de la demande internationale PCT/US2004/019485
Date du dépôt international 18.06.2004
CIB
C12N 9/12 2006.01
CCHIMIE; MÉTALLURGIE
12BIOCHIMIE; BIÈRE; SPIRITUEUX; VIN; VINAIGRE; MICROBIOLOGIE; ENZYMOLOGIE; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE
NMICRO-ORGANISMES OU ENZYMES; COMPOSITIONS LES CONTENANT; CULTURE OU CONSERVATION DE MICRO-ORGANISMES; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE; MILIEUX DE CULTURE
9Enzymes, p.ex. ligases (6.); Proenzymes; Compositions les contenant; Procédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
10Transférases (2.)
12transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
CPC
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
G01N 33/5008
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
G01N 33/5011
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
5011for testing antineoplastic activity
G01N 33/5026
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
502for testing non-proliferative effects
5026on cell morphology
G01N 33/5091
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5091for testing the pathological state of an organism
Y10T 436/143333
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
436Chemistry: analytical and immunological testing
14Heterocyclic carbon compound [i.e. , O, S, N, Se, Te, as only ring hetero atom]
142222Hetero-O [e.g., ascorbic acid, etc.]
143333Saccharide [e.g., DNA, etc.]
Déposants
  • EXELIXIS, INC. [US/US]; P.O. Box 511 170 Harbor Way South San Francisco, CA 94083-0511, US (AllExceptUS)
  • PLOWMAN, Gregory, D. [US/US]; US (UsOnly)
  • KARIM, Felix, D. [US/US]; US (UsOnly)
  • SWIMMER, Candace [US/US]; US (UsOnly)
  • HABECK, Hinrich, Alexander [DE/DE]; DE (UsOnly)
  • KOBLIZEK, Thomas, I. [DE/DE]; DE (UsOnly)
  • SCHULTE-MERKER, Stefan [DE/DE]; DE (UsOnly)
  • LANGHEINRICH, Ulrike [DE/DE]; DE (UsOnly)
  • STOTT, Gordon, Mark [DE/US]; US (UsOnly)
  • TROWE, Torsten [DE/DE]; DE (UsOnly)
  • VOGEL, Andreas, Michael [DE/DE]; DE (UsOnly)
  • ODENTHAL, Joerg, Heinrich [DE/DE]; DE (UsOnly)
  • SCHEEL, Jochen, Konrad [DE/DE]; DE (UsOnly)
  • WILL, Torsten, Tilmann [DE/DE]; DE (UsOnly)
  • JIN, Yisheng [CN/US]; US (UsOnly)
  • BJERKE, Lynn, Margaret [US/US]; US (UsOnly)
  • HEUER, Timothy, S. [US/US]; US (UsOnly)
Inventeurs
  • PLOWMAN, Gregory, D.; US
  • KARIM, Felix, D.; US
  • SWIMMER, Candace; US
  • HABECK, Hinrich, Alexander; DE
  • KOBLIZEK, Thomas, I.; DE
  • SCHULTE-MERKER, Stefan; DE
  • LANGHEINRICH, Ulrike; DE
  • STOTT, Gordon, Mark; US
  • TROWE, Torsten; DE
  • VOGEL, Andreas, Michael; DE
  • ODENTHAL, Joerg, Heinrich; DE
  • SCHEEL, Jochen, Konrad; DE
  • WILL, Torsten, Tilmann; DE
  • JIN, Yisheng; US
  • BJERKE, Lynn, Margaret; US
  • HEUER, Timothy, S.; US
Mandataires
  • SHAYESTEH, Laleh ; Exelixis, Inc. P.O. Box 511 170 Harbor Way South San Francisco, CA 94083-0511, US
Données relatives à la priorité
60/479,78119.06.2003US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) MYLKS AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
(FR) GENE MYLK UTILISE EN TANT QUE MODIFICATEUR DE LA MORPHOGENESE RAMIFIEE ET PROCEDES D'UTILISATION CORRESPONDANT
Abrégé
(EN)
Human MYLK genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MYLK are provided.
(FR)
L'invention concerne des gènes MYLK humains identifiés en tant que modulateurs de la morphogenèse ramifiée, consistant donc en des cibles thérapeutiques contre des troubles associés à une fonction défectueuse de la morphogenèse ramifiée. Les procédés d'identification de modulateurs de morphogenèse ramifiée consistent à cribler des agents qui modulent l'activité de MYLK.
Également publié en tant que
Dernières données bibliographiques dont dispose le Bureau international